Profil Financier
Hu Kaijun occupe actuellement le rang #1431 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $2.9 B (+$106 sur 24h).
Hu Kaijun is chairman and CEO of China Grand Enterprises, an investment company with interests in healthcare, real estate, agriculture and financial services.
China Grand is the parent of three publicly-traded companies: Grand Pharmaceutical, Huadong Medicine (a wholesaler) and Grand Industrial Holding (a trading business).
Grand Pharmaceutical agreed to buy 87.5% of U.S.-based vascular drug maker BlackSwan Vascular for $37.5 million in 2023.
Hu also wholly owns Beijing Yuanda Huachuang Investment, where he also serves as chairman and CEO.
Hu's wealth is derived primarily from Grand China's stakes in Huadong Medicine and Grand Pharmaceutical.